Intellia Therapeutics (NTLA) Non Operating Income (2021 - 2026)

Intellia Therapeutics (NTLA) has 6 years of Non Operating Income data on file, last reported at $4.3 million in Q1 2026.

• Quarterly Non Operating Income fell 33.61% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.1 million (up 72.37% YoY) and the FY2025 annual result came in at $28.3 million, up 85.64% from the prior year.
• Non Operating Income grew to $4.3 million in Q1 2026 per NTLA's latest filing, from $2.9 million in the prior quarter.
• Across five years, Non Operating Income topped out at $10.2 million in Q3 2025 and bottomed at -$7.9 million in Q2 2024.
• The 5-year median for Non Operating Income is $6.6 million (2024), against an average of $3.9 million.
• The widest annual swing landed in 2022, when Non Operating Income sank 2306.02%; it then jumped 464.03% in 2023.
• Tracing NTLA's Non Operating Income over 5 years: stood at -$3.3 million in 2022, then soared by 332.86% to $7.7 million in 2023, then decreased by 2.35% to $7.5 million in 2024, then slumped by 61.27% to $2.9 million in 2025, then soared by 47.09% to $4.3 million in 2026.
• Per Business Quant, the three latest NTLA Non Operating Income figures stand at $4.3 million (Q1 2026), $2.9 million (Q4 2025), and $10.2 million (Q3 2025).

Peer Comparison